Press releases
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
As of last trade Halozyme Therapeutics Inc (RV7:BER) traded at 47.56, -2.48% below its 52-week high of 48.77, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.56 |
---|---|
High | 47.56 |
Low | 47.56 |
Bid | 47.45 |
Offer | 47.78 |
Previous close | 48.27 |
Average volume | 118.22 |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 21.22 |
Market cap | 6.53bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:08 BST.
More ▼